Still’s Disease Treatment Market, By Treatment, By Route of Administration, By Distribution Channels and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Aug 2023

Code : CMI4023

Pages :255

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Still’s Disease Treatment Market: Key Developments

On January 6, 2022, Avalo Therapeutics, Inc., a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology and rare genetic diseases, provided a comprehensive update on the company’s growth opportunities and mid-stage development portfolio. AVTX-007 is being evaluated in a multicenter, Phase 1b study in 12 refractory or steroid-dependent patients with Adult Onset Still’s Disease in two cohorts. Top-line data for both cohorts of the trial were obtained by mid-year 2022.

On December 22, 2020 Cerecor Inc., a biopharmaceutical company focused on development and commercialization of treatments for rare and orphan diseases, announced that its Investigational New Drug Application (IND) to study the use of CERC-007 to treat Still’s disease has been accepted by the U.S. Food and Drug Administration (FDA) and is now open. CERC-007 is a high affinity, fully human anti-IL-18 monoclonal antibody (mAb). The first study will be a global multicenter Phase 1b clinical trial in adult onset Still’s disease and started in the first quarter of 2021. Initial data is expected in the second quarter of 2021.